Evidence map›Paper›PMID 33801197›Full record

ArticleJournal of clinical medicine2021

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage.

Paula Marazuela, Anna Bonaterra-Pastra, Júlia Faura, Anna Penalba, Jesús Pizarro, Olalla Pancorbo, David Rodríguez-Luna, Carla Vert, Alex Rovira, Francesc Pujadas and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Aquaporin-4 and Cognitive Disorders.Aging and disease · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Paula MarazuelaNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Anna Bonaterra-PastraNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Júlia FauraNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Anna PenalbaNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Jesús PizarroNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Olalla PancorboStroke Unit, Department of Neurology, Vall d'Hebron Hospital, 08035 Barcelona, Spain.
David Rodríguez-LunaStroke Unit, Department of Neurology, Vall d'Hebron Hospital, 08035 Barcelona, Spain.
Carla VertNeuroradiology, Department of Radiology, Vall d'Hebron Hospital, 08035 Barcelona, Spain.
Alex RoviraNeuroradiology, Department of Radiology, Vall d'Hebron Hospital, 08035 Barcelona, Spain.ORCID 0000-0002-2132-6750
Francesc PujadasDementia Unit, Neurology Department, Vall d'Hebron Hospital, 08035 Barcelona, Spain.
M Mar FreijoNeurovascular Group, Biocruces Health Research Institute, 48903 Barakaldo, Spain.
Silvia TurNeurology, Son Espases University Hospital, 07120 Balearic Islands, Spain.
Maite Martínez-ZabaletaDepartment of Neurology, Donostia University Hospital, 20080 San Sebastián, Spain.
Pere Cardona PortelaDepartment of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Rocío VeraStroke Unit, Department of Neurology, Ramon y Cajal University Hospital, 28034 Madrid, Spain.
Lucia Lebrato-HernándezStroke Unit, Virgen del Rocío University Hospital, 41013 Sevilla, Spain.
Juan F ArenillasStroke Program, Department of Neurology, Hospital Clínico Universitario, 47003 Valladolid, Spain.
Soledad Pérez-SánchezDepartment of Neurology, Virgen Macarena University Hospital, 41009 Sevilla, Spain.ORCID 0000-0002-8940-9763
Joan MontanerNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Pilar DelgadoNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Mar Hernández-GuillamonNeurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Universitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ESBellvitge University Hospital · ESBioCruces Health research Institute · ESBiogipuzkoa Health Research Institute · ESHospital Universitario Son Espases · ESHospital Universitario Virgen del Rocío · ESHospital Universitario Virgen Macarena · ESInstituto Cajal · ESUniversidad de Valladolid · ES

Funding

Instituto de Salud Carlos III PI17/00275Instituto de Salud Carlos III RD16/0019/0021
6 · The paper itself

Abstract

Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA-ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH.

Indexed as

aquaporin 4cerebral amyloid angiopathyfunctional outcomeintracerebral hemorrhagemagnetic resonance imaging markers

Identifiers

PMID33801197
PMCPMC7957864
OpenAlexW3135651539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.